Table 1.
Final General PharmacoDynamic Interaction (GPDI) model parameter estimates and their 95% confidence intervals (CI) for the interaction between erlotinib and bortezomib in the non-small cell lung cancer cell line HCC4006 and HCC4006rErlo0.5 which has been adapted to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib. AIC: Akaike Information Criterion, EC50: Drug potency, the concentration at which half of the maximum effect is reached, Emax: Maximum effect, H: Hill coefficient, sigmoidity of the concentration–effect relationship, GPDIINT: GPDI interaction parameter, maximal effect of perpetrator on victim, EC50,INT: Potency of the interaction, concentration of the perpetrator at which half of the maximum effect on the victim is reached, NA: not applied.
| Parameters | HCC4006 | HCC4006rErlo0.5 | |
|---|---|---|---|
| AIC | −565 | −408 | |
| Erlotinib | EC50 [nM] (95% CI) | 35.2 (29.5–40.9) | 3770 (−980–8514) |
| Emax (95% CI) | 0.586 (0.573–0.600) | 0.426 (0.306–0.546) | |
| H (95% CI) | 3.15 (1.90–4.41) | 0.272 (0.157–0.387) | |
| Bortezomib | EC50 [nM] (95% CI) | 73.0 (60.4–111) | 52.4 (46.1–58.8) |
| Emax (95% CI) | 0.585 (0.568–0.622) | 0.911 (0.867–0.954) | |
| H (95% CI) | 20.7 (−35.2–115) | 1.47 (1.19–1.75) | |
| Erlotinib effect on bortezomib Emax | GDPIINT (95% CI) | −0.492 (−0.595–−0.389) | 0 |
| EC50,INT [nM] (95% CI) | 69.6 (38.6–101) | NA | |
| Bortezomib effect on erlotinib Emax | GDPI_INT (95% CI) | −0.546 (−0.713–−0.380) | 0 |
| EC50,INT [nM] (95% CI) | 117 (64.5–170) | NA |